Relapse-Free Survival With Adjuvant Dabrafenib/Trametinib Therapy in Patients With BRAF V600-mutated Stage III/IV Melanoma
Clinical trial NCT06557291 · COMPLETED
Trial details
- NCT number
- NCT06557291
- Sponsor
- Novartis
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2022-10-04
- Primary completion
- 2023-11-16
- Enrollment
- 38
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.